Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced Malignancies: early-phase trial registry
2 of 11 indexed Advanced Malignancies trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 2 currently recruiting · #1,577 of 28,707 conditions by registered trial count
Advanced Malignancies: 11 US clinical trials tracked, 2 recruiting.
Advanced Malignancies is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Novartis Pharmaceuticals, running 2 of these trials.
Enrollment posture brief
Registry condition advanced-malignancies
OPEN 2 | RECR 18% | LATE 2 | EARLY 9 | RANK #1577 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome (18% recruiting · 22 trials)
Advanced Malignancies lists 2 open slots (18% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced Malignancies on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced Malignancies is recruiting below its size-band peers.
2 of 11 indexed trials (18.2%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Advanced Malignancies research.
Novartis Pharmaceuticals accounts for 2 of 11 trials (18.2%). 10 distinct sponsors appear on at least one study for this condition label.
-
Most Advanced Malignancies trials plan to enrol fewer than 100 people.
Median target enrolment is 46 among the 11 trials that report a genuine target (sentinel values excluded). 9 of those (81.8%) plan for fewer than 100 participants.
-
Advanced Malignancies research is mostly interventional.
11 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
BioInvent International AB
NCT04752826
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Novartis Pharmaceuticals
NCT06401356
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Pfizer
NCT05059522
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Arcus Biosciences
NCT05891171
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
Regeneron Pharmaceuticals
NCT02383212
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
MedImmune
NCT02013804
Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)
Astellas Pharma
NCT01284192
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen
Astellas Pharma Global Development
NCT04837196
Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State
Mirati Therapeutics
NCT01930006
A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function
Novartis Pharmaceuticals
NCT00421044
Maintenance Study on the Long Term Safety of XL999
Symphony Evolution
NCT00955084
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced Malignancies records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced Malignancies trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced Malignancies page
11 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Advanced Malignancies trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Novartis Pharmaceuticals sponsors the most Advanced Malignancies trials on record, review their full trial history before evaluating a specific study. See Novartis Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Malignancies condition card totals 11 registered trials; most-linked intervention Patupilone/EPO906; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.